EFFECTS OF TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR, OR ADALIMUMAB ON PATIENT REPORTED OUTCOMES IN A PHASE 3 STUDY OF ACTIVE RHEUMATOID ARTHRITIS

被引：1

作者：

van Vollenhoven, R. F. ^{[1
]}

Wallenstein, G. ^{[2
]}

Lee, E. B. ^{[3
]}

Fleischmann, R. ^{[4
]}

Zwillich, S. H. ^{[2
]}

Gruben, D. ^{[2
]}

Koncz, T. ^{[5
]}

Bradley, J. ^{[2
]}

Wilkinson, B. ^{[2
]}

Strand, V. ^{[6
]}

机构：

[1] Karolinska Inst, Stockholm, Sweden

[2] Pfizer Inc, Groton, CT USA

[3] Seoul Natl Univ, Seoul, South Korea

[4] Metroplex Clin Res Ctr, Dallas, TX USA

[5] Pfizer Inc, New York, NY USA

[6] Stanford Univ, Palo Alto, CA 94304 USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2013年 / 71卷

关键词：

D O I：

10.1136/annrheumdis-2012-eular.2116

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：206 / 206

页数：1

共 50 条

[1] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, or Adalimumab Versus Placebo in Patients with Rheumatoid Arthritis on Background Methotrexate: A Phase 3 Study.
van Vollenhoven, R. F.
Fleischmann, R. M.
Cohen, S. B.
Lee, E. B.
Meijide, G.
Wagner, S.
Forejtova, S.
Zwillich, S. H.
Gruben, D.
Koncz, T.
Wallenstein, G.
Krishnaswami, S.
Bradley, J. D.
Wilkinson, B.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S153 - S153
[2] Tofacitinib (CP-690,550), an oral Janus Kinase inhibitor: pooled phase 3 analysis in a German rheumatoid arthritis study population
Schulze-Koops, H.
Rubbert-Roth, A.
Behmer, O.
Kerkmann, U.
Kwok, K.
Burkhardt, H.
[J]. ZEITSCHRIFT FUR RHEUMATOLOGIE, 2013, 72 : 11 - 11
[3] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: POOLED PHASE 3 ANALYSIS IN AN AUSTRALIAN RHEUMATOID ARTHRITIS STUDY POPULATION
Hall, S.
Nash, P.
Rischmueller, M.
Bossingham, D.
Cook, N.
Kwok, K.
Thirunavukkarasu, K.
[J]. INTERNAL MEDICINE JOURNAL, 2012, 42 : 14 - 14
[4] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF MALIGNANCIES ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Marlette, X.
Curtis, J. R.
Lee, E. B.
Riese, R.
Kaplan, I.
Chew, R.
Geier, J.
Wang, L.
Bradley, J. D.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 199 - 199
[5] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSES OF EFFICACY ENDPOINTS BY SUBGROUPS IN A POOLED PHASE 2 AND 3 RHEUMATOID ARTHRITIS STUDY POPULATION
Kremer, J.
Zerbini, C.
Lee, E. B.
Gruben, D.
Krishnaswami, S.
Zwillich, S. H.
Koncz, T.
Bradley, J.
Mebus, C. A.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 203 - 204
[6] Phase 2 Study of CP-690,550, an Oral Janus Kinase Inhibitor, in Active Ulcerative Colitis
Sandborn, William J.
Ghosh, Subrata
Panes, Julian
Varnic, Ivana
Su, Chinyu
Spanton, J.
Niezychowski, Wojciech
[J]. GASTROENTEROLOGY, 2011, 140 (05) : S110 - S110
[7] The discovery of CP-690,550: A potent Janus kinase 3 inhibitor for the treatment of rheumatoid arthritis
Flanagan, Mark E.
[J]. ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2009, 238
[8] Tofacitinib (CP-690,550), a Janus Kinase Inhibitor for Dry Eye Disease
Liew, Shiao Hui
Nichols, Kelly K.
Klamerus, Karen J.
Li, Jim Z.
Zhang, Min
Foulks, Gary N.
[J]. OPHTHALMOLOGY, 2012, 119 (07)
[9] TOFACITINIB (CP-690,550), AN ORAL JANUS KINASE INHIBITOR: ANALYSIS OF GASTROINTESTINAL ADVERSE EVENTS ACROSS THE RHEUMATOID ARTHRITIS CLINICAL PROGRAMME
Lee, E. B.
Curtis, J. R.
Riese, R.
Connell, C.
Chew, R.
Boy, M.
Maller, E.
Su, C.
Wang, L.
Bradley, J.
[J]. ANNALS OF THE RHEUMATIC DISEASES, 2013, 71 : 202 - 203
[10] Tofacitinib (CP-690,550), An Oral Janus Kinase Inhibitor, As Monotherapy in Japanese Patients with Active Rheumatoid Arthritis: A 12-Week Phase 2b Study
Tanaka, Y.
Takeuchi, T.
Yamanaka, H.
Suzuki, M.
Nakamura, H.
Toyoizumi, S.
Bradley, J. D.
Zwillich, S. H.
[J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S854 - S855

← 1 2 3 4 5 →